Prevalence of and risk factors for pre-diabetes in HIV-1-infected patients in Bangkok, Thailand

Journal of the International Association of Physicians in AIDS Care

Volumn 9, Issue 6, 2010, Pages 358-361

  Srivanich, Nopporn ^a   Ngarmukos, Chardpraorn ^a   Sungkanuparph, Somnuek ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

diabetes; HIV 1; nevirapine; pre diabetes; risk factor

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; NEVIRAPINE;

ADULT; ARTICLE; BODY WEIGHT; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DIET RESTRICTION; ENDOCRINE DISEASE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRE DIABETES; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; THAILAND;

ADULT; ANTI-HIV AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; NEVIRAPINE; PREDIABETIC STATE; PREVALENCE; RISK FACTORS; THAILAND;

EID: 78650837134     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/1545109710373832     Document Type: Article

References (24)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med. 1998 ; 338 (13). 853-860.
2. Manosuthi W., Chottanapand S., Thongyen S., Chaovavanich A., Sungkanuparph S. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr. 2006 ; 43 (1). 42-46.
3. Behrens G., Dejam A., Schmidt H., et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS. 1999 ; 13 (10). F63 - F70.
4. Friis-Moller N., Sabin CA, Weber R., et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003 ; 349 (21). 1993-2003.
5. Justman JE, Benning L., Danoff A., et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr. 2003 ; 32 (3). 298-302.
6. Ledergerber B., Furrer H., Rickenbach M., et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis. 2007 ; 45 (1). 111-119.
7. Mulligan K., Grunfeld C., Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr. 2000 ; 23 (1). 35-43.
8. Sabin CA, Worm SW, Weber R., et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008 ; 371 (9622). 1417-1426.
9. De Wit S., Sabin CA, Weber R., et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the data collection on adverse events of anti-HIV drugs (D:A:D) study. Diabetes Care. 2008 ; 31 (6). 1224-1229.
10. Brown TT, Cole SR, Li X., et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005 ; 165 (10). 1179-1184. (Pubitemid 40720744)
11. Tien PC, Schneider MF, Cole SR, et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Inter-agency HIV Study. AIDS. 2007 ; 21 (13). 1739-1745.
12. Chantrathamachart P., Sungkanuparph S., Kietiburanakul S., Malathum K. Diabetes mellitus and hypertension in HIV-infected patients receiving antiretroviral therapy: a pilot study. J Infect Dis Antimicrob Agents. 2006 ; 23 (3). 131-138.
13. Katabira ET, Oelrichs RB Scaling up antiretroviral treatment in resource-limited settings: successes and challenges. AIDS. 2007 ; 21 (suppl 4). S5 - S10.
14. Manosuthi W., Chimsuntorn S., Likanonsakul S., Sungkanuparph S. Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 > or = 50 cells/mm3. AIDS. Res Ther. 2007 ; 4 (1). 6.
15. Kiertiburanakul S., Khongnorasat S., Rattanasiri S., Sungkanuparph S. Efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) in Thai HIV-infected patients. J Med Assoc Thai. 2007 ; 90 (2). 237-243. (Pubitemid 46377158)
16. Sungkanuparph S., Manosuthi W., Kiertiburanakul S., Vibhagool A. Initiation of antiretroviral therapy in advanced AIDS with active tuberculosis: clinical experiences from Thailand. J Infect. 2006 ; 52 (3). 188-194.
17. American Diabetes Association. Diagnosis and description of diabetes mellitus. Diabetes Care. 2010 ; 33 (suppl 1). S62 - S629.
18. American Diabetes Association. Executive summary: standards of medical care in diabetes-2010. Diabetes Care. 2010 ; 33 (suppl 1). S4 - S10.
19. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004 ; 363 (9403). 157-163.
20. Aekplakorn W., Stolk RP, Neal B., et al. INTERASIA Collaborative Group. The prevalence and management of diabetes in Thai adults: the international collaborative study of cardiovascular disease in Asia. Diabetes Care. 2003 ; 26 (10). 2758-2763.
21. Manosuthi W., Chottanapand S., Thongyen S., Chaovavanich A., Sungkanuparph S. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr. 2006 ; 43 (1). 42-46.
22. Manosuthi W., Sungkanuparph S., Vibhagool A., Rattanasiri S., Thakkinstian A. Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV infection. HIV Med. 2004 ; 5 (2). 105-109.
23. Manfredi R., Calza L., Chiodo F. An extremely different dysmetabolic profile between the two available non-nucleoside reverse transcriptase inhibitors: efavirenz and nevirapine. J Acquir Immune Defic Syndr. 2005 ; 38 (2). 236-238.
24. van Leth F., Phanuphak P., Stroes E., et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med. 2004 ; 1 (1). e19.